Apr 1, 2020   SOURCE: PR NewsWire

Global Activin Receptor Type 1 Pipeline & Therapeutic Landscape Assessment, 2020

DUBLIN, April 1, 2020 /PRNewswire/ -- The "Activin Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

According to the report, the pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

This report outlays comprehensive information on the Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Activin Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report Scope

    --  The report provides a snapshot of the global therapeutic landscape for
        Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or
        Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily
        Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30)
    --  The report reviews Activin Receptor Type 1 (Activin Receptor Like Kinase
        2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily
        Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics
        under development by companies and universities/research institutes
        based on information derived from company and industry-specific sources
    --  The report covers pipeline products based on various stages of
        development ranging from pre-registration till discovery and undisclosed
        stages
    --  The report features descriptive drug profiles for the pipeline products
        which includes, product description, descriptive MoA, R&D brief,
        licensing and collaboration details & other developmental activities
    --  The report reviews key players involved in Activin Receptor Type 1
        (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase
        Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC
        2.7.11.30) targeted therapeutics and enlists all their major and minor
        projects
    --  The report assesses Activin Receptor Type 1 (Activin Receptor Like
        Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B
        Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted
        therapeutics based on mechanism of action (MoA), route of administration
        (RoA) and molecule type
    --  The report summarizes all the dormant and discontinued pipeline projects
    --  The report reviews latest news and deals related to Activin Receptor
        Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein
        Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1
        or EC 2.7.11.30) targeted therapeutics

Featured News & Press Releases

    --  Dec 07, 2019: Sierra Oncology reports decreased transfusion requirements
        for patients treated with Momelotinib directly compared to Ruxolitinib
        at ASH annual meeting
    --  Dec 02, 2019: Sierra Oncology announces investor event to discuss
        Momelotinib data being reported at ASH
    --  Nov 21, 2019: Sierra Oncology initiates study of momelotinib in
        myelofibrosis
    --  Nov 06, 2019: Sierra Oncology to report new analyses supporting
        Momelotinib's anemia benefits at ASH 2019
    --  Nov 04, 2019: BioCryst launches trial to treat fibrodysplasia ossificans
        progressiva
    --  Oct 24, 2019: Oncodesign: publication of an article presenting promising
        results for the treatment of stone man syndrome (FOP)
    --  Jun 27, 2019: Sierra Oncology launches campaign exploring non-dilutive
        strategic options to support development of its DDR Assets
    --  Jun 07, 2019: FDA grants fast-track designation to bone marrow cancer
        drug
    --  Jun 04, 2019: Sierra announces FDA regulatory clarity for Momelotinib &
        design of the MOMENTUM phase 3 clinical trial
    --  May 28, 2019: Sierra Oncology to Present Momelotinib Overview at the
        Jefferies Global Healthcare Conference in New York
    --  Mar 27, 2019: Blueprint Medicines provides update on clinical progress
        of BLU-782
    --  Feb 27, 2019: Tolero Pharmaceuticals to present new data evaluating
        investigational agent TP-0184 at AACR Annual Meeting 2019
    --  Dec 03, 2018: Sierra Oncology reports robust transfusion independence
        rates in transfusion dependent myelofibrosis patients treated with
        momelotinib
    --  Nov 27, 2018: Sierra Oncology to host analyst call highlighting clinical
        data on Momelotinib's anemia benefit

    --  Nov 01, 2018: Sierra Oncology to report clinical data at ASH 2018 from
        translational biology study of Momelotinib in transfusion

Companies Mentioned 

    --  BioCryst Pharmaceuticals Inc
    --  Clementia Pharmaceuticals Inc
    --  Daiichi Sankyo Co Ltd
    --  Incyte Corp
    --  Keros Therapeutics Inc
    --  La Jolla Pharmaceutical Company
    --  M4K Pharma Inc
    --  Oncodesign SA
    --  Sierra Oncology Inc
    --  Tolero Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m9euzr

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-activin-receptor-type-1-pipeline--therapeutic-landscape-assessment-2020-301033571.html

SOURCE Research and Markets